Jason Harris

Jun 3, 2024 | cancernetwork.com | Jason Harris

Disease recurrence, minimal residual disease (MRD) status, and clinical benefit with adjuvant atezolizumab (Tecentriq) among those with renal cell carcinoma (RCC) may correlate with the presence of circulating kidney injury molecule-1 (KIM-1), according to retrospective data from the phase 3 IMmotion010 trial (NCT03024996) presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Previously reported topline results from the IMmotion010 trial showed that atezolizumab...

Oct 7, 2023 | curetoday.com | Jason Harris

Patients with relapsed/refractory multiple myeloma benefited from treatment with MCARH109, a CAR-T cell therapy targeting the “enigmatic” GPRC5D antigen which generated remissions in 70.6% of patients, according to data from a first-in-human phase 1 trial. Twelve of 17 patients experienced a measurable decline in their cancer after receiving MCARH109 CAR-T cells. Six patients (35%) achieved complete response and 10 patients (59%) had very good partial response or better.

Apr 11, 2023 | onclive.com | Jason Harris

Apr 8, 2023 | oncnursingnews.com | Jason Harris

Apr 8, 2023 | ajmc.com | Jason Harris